Recently, it has been reported that GV1001 is a novel ligand for the gonadotropin-releasing hormone receptor (GnRHR) by selectively stimulating the Gαs/cAMP pathway, suggesting the possibility of a treatment for Alzheimer’s disease as well as cancer [14]. This evidence concerns the gene GNRHR and early-onset autosomal dominant Alzheimer disease.